---
title: "Varegacestat (AL102) in Desmoid tumors: Definition and etiology"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Definition and etiology. Topics: Definition: monoclonal fibroblastic proliferation with a variable clinical course; WHO 2020 classification: intermediate, locally aggressive category; Locally aggressive tumor without metastatic potential; Sporadic and familial adenomatous polyposis-associated desmoid tumors; 7 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: monoclonal fibroblastic proliferation with a variable clinical course

> “Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable clinical course.”
> “In the International Classification of Diseases (ICD) it is classified as D48.1.”
> “According to the World Health Organisation (WHO), DT is a”
> “clonal fibroblastic proliferation that arises in the deep soft tissues and is characterised by infiltrative growth and a tendency toward local recurrence but an inability to metastasise”
> “even though it may be multifocal in the same limb or body part”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.1-2"></a>

### WHO 2020 classification: intermediate, locally aggressive category

> “category of lesions that can be either locally aggressive (i.e. desmoid fibromatosis) or rarely metastasizing (i.e. plexiform fibrohistiocytic tumour).”

Source: [Sbaraglia et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/)

<a id="topic-2.2.1.1-3"></a>

### Locally aggressive tumor without metastatic potential

> “Although lacking metastatic potential, DT is often locally aggressive and invasive, causing significant morbidity.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Desmoid tumors, also known as aggressive fibromatosis or desmoid-type fibromatosis, are rare, non-metastatic, locally aggressive sarcomas of fibroblastic origin.”
> “Desmoid tumors arise in connective tissue and can occur anywhere in the body where connective tissue is found. These tumors are locally aggressive, which means that while they do not metastasize to other parts of the body, they can grow into the surrounding or adjacent tissue.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-4"></a>

### Sporadic and familial adenomatous polyposis-associated desmoid tumors

> “Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC , respectively.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “DT may occur at abdominal, intra-abdominal, and extra-abdominal locations and approximately 5–10% arise in the context of familial adenomatous polyposis (FAP).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “The vast majority (85-90%) of desmoid tumors are sporadic and of these, 85% result from somatic mutations in the CTNNB1 gene, which encodes β-catenin protein.”
> “Desmoid tumors may also result from germline mutation of the APC gene, which is also associated with familial adenomatous polyposis, that leads to accumulation of β-catenin in the nucleus and drives overexpression of its target genes.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-5"></a>

### Proportion with familial adenomatous polyposis in a Dutch nationwide pathology registry, 1999 to 2009

> “Histopathology data of all Dutch patients with desmoid-type fibromatoses diagnosed between 1999 and 2009 were retrieved from PALGA, the nation-wide network and registry of histopathology in the Netherlands.”
> “A total number of 519 patients older than 10 years with a confirmed diagnosis of desmoid-type fibromatoses were included. Thirty-nine (7.5%) desmoid patients were documented of having FAP.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.1-6"></a>

### Frequency of CTNNB1 mutations

> “CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids.”
> “Three discrete mutations in two codons of CTNNB1 exon 3 were identified: 41A (59%), 45F (33%), and 45P (8%, excluded from further analysis because of rarity).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.”
> “In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P.”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

<a id="topic-2.2.1.1-7"></a>

### Risk factor: antecedent trauma, including prior surgery

> “In 164 patients (32.7%), a trauma anteceding DT could be verified with a median lag time of 22.9 months (SD, 7.7 months; range, 9-44 months).”
> “A prior surgical procedure was relevant in 98 patients, a blunt trauma in 35 patients, a punctuated trauma (injections, trocar) in 18 patients, and site of an implant in 10 patients.”
> “The distribution of mutations in the CTNNB1 gene (codon 41 vs. 45) was similar in patients with and without a history of trauma before DT development.”

Source: [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/)

<a id="topic-2.2.1.1-8"></a>

### Risk factors: pregnancy and estrogen

> “In 220 patients, no trauma was reported (43.9%), and 58 females (11.6%) had a postpregnancy DT in the rectus abdominis muscle.”

Source: [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/)

> “It has been observed that DT may occur in association with pregnancy and with the use of estrogen-containing oral contraceptives”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Risk factors for developing desmoid tumors in patients with these mutations include trauma (especially abdominal surgery), estrogen, and pregnancy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-9"></a>

### Desmoid risk in familial adenomatous polyposis: U.S. community cohort

> “We conducted a retrospective cohort study of patients with pathogenic or likely pathogenic variants (PV/LPV) in APC identified through the Kaiser Permanente Northern California Electronic Database, a community-based system serving 4.6 million members.”
> “Among 328 patients with FAP, 36 (11.0%) developed DT. DT risk was highest when the APC variant was centrally located (codon 600-1600).”
> “All colorectal surgeries were associated with a significantly elevated DT risk: ileostomy (aOR 12.07; 2.10-69.47), subtotal colectomy with ileorectal anastomosis (aOR 9.03; 1.63-49.96), and total proctocolectomy with ileal pouch-anal anastomosis (aOR 10.98; 2.12-56.81).”
> “In this large community-based U.S. cohort, central APC variant location, family history, and colorectal surgery were associated with increased DT risk.”

Source: [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/)

<a id="topic-2.2.1.1-10"></a>

### Desmoid risk after risk-reducing colectomy in familial adenomatous polyposis by APC genotype and family history

> “This study aimed to quantify absolute postoperative desmoid risk in FAP patients undergoing risk-reducing colectomy, stratified by APC genotype, and to assess the modifying effect of family history.”
> “This retrospective observational study used records from a prospectively maintained registry.”
> “Among 48 high-risk patients, 30 (63%) developed desmoid, with no significant difference between colectomy and proctocolectomy (54% versus 70%, respectively; χ 2 = 1.42; P = 0.233).”
> “Among the 1213 low-risk patients, 154 (12.7%) developed desmoids, with no significant effect of surgical procedure (13.9% versus 12.1% for proctocolectomy and total/partial colectomy, respectively; χ² = 0.77; P = 0.380).”
> “A family history of desmoid disease appears to be an important determinant of postoperative desmoid risk in FAP.”

Source: [Zare et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13591399/)

<a id="topic-2.2.1.1-11"></a>

### Desmoid risk in a familial adenomatous polyposis cohort of 735 patients

> “The medical records of 735 FAP patients were analyzed for the occurrence of desmoids.”
> “Desmoid tumors were identified in 66 of the 735 patients (9%). The cumulative risk of developing desmoids was 14%.”
> “Patients with a positive family history for desmoids had a significant increased risk to develop this tumor (30% vs 6.7%, P < .001).”
> “Most desmoid patients (95%) had undergone previous abdominal surgery.”

Source: [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
